Thomas J. Prins

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes

David A. Matthews, Peter S. Dragovich, S. E. Webber et al. · Proceedings of the National Academy of Sciences · 1999 · 318 citations · Full text

Life Sciences, Biochemistry, Biology +17

In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

Amy K. Patick, Susan L. Binford, M. A. Brothers et al. · Antimicrobial Agents and Chemotherapy · 1999 · 224 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as <scp>l</scp>-Glutamine Replacements

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 1999 · 189 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure−Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2002 · 142 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2003 · 115 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17